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With an increasing global cancer burden, new methods of cancer prevention are 
desired to improve overall survival. In particular, pancreatic cancer (PC) is in desperate 
need of new strategies to improve the dismal 8% overall 5-year survival rate. Studies 
have shown aberrant activation of the Hedgehog pathway to be associated with very 
poor prognosis in multiple cancer types, including pancreatic. Prevention strategies 
utilizing dietary agents have been shown to regulate multiple cancer hallmark pathways, 
but little is known regarding their effect on Hedgehog. Here we observed diallyl 
trisulfide (DATS), an anti-cancer agent found in garlic, reduced colony formation and 
inhibited Hedgehog signaling in PC cells. Treatment of AsPC-1 PC cells with DATS 
resulted in inhibition of mRNA and protein expression of the transcription factor Gli1. 
Protein levels of the Sonic Hedgehog pathway initiating ligand as well as the Patched 
receptor were increased following DATS treatment. Additionally, DATS reduced ectopic 
expression of Gli1. These results give further support for the anti-cancer role of DATS 




CHAPTER 1. INTRODUCTION 
In the United States, an estimated 1.6 million people will be diagnosed with 
cancer leading to 595,000 deaths in 2016 [1]. The American Cancer Society has 
estimated that the global cancer burden will grow from 12.3 million cases and 7.6 
million deaths in 2007 [2] to nearly 22 million new cases and 13 million deaths by the 
year 2030 [3]. A 2007 report by the World Health Organization also estimated that by 
the year 2010, cancer would overtake ischemic heart disease as the leading cause of 
death globally [4]. In 2016, cancer has become the leading cause of death in 21 states in 
the United States [1], but remains the second leading cause of death in high income 
countries, and the third leading cause of death in developing countries [3]. So while over 
1.7 million cancer-related deaths have been averted since 1991 in the United States 
alone [1], cancer remains a serious present and future public health concern. 
Pancreatic cancer (PC), with just an 8% overall 5-year survival rate, is a large 
source of cancer related mortality in the United States and around the world [1]. While 
PC is estimated to represent just over 3% of new cancer cases, the 41,780 deaths 
estimated to be attributed to PC in 2016 ranks third behind lung cancer and colorectal 
cancer [1]. Of the various types of PC, pancreatic ductal adenocarcinoma (PDAC) 
represents about 90% of cases and is nearly always fatal [5]. In general, PC tumors are 
classified as resectable, locally advanced (which is further divided into borderline 
resectable and non-resectable groups), or advanced [6–9]. The median overall survival 
ranges from 20-24 months for primarily resectable tumors [7] to less than 12 months 
from the time of diagnosis for patients with advanced PC [8]. According to the 2016 
Cancer Statistics Report, over 50% of patients present after distant metastasis has 
occurred while just 9% of cases are diagnosed early enough that surgery, currently the 
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most successful curative option, is a viable prospect [1, 9]. In patients who undergo 
surgery, adjuvant chemoradiation and/or chemotherapy using gemcitabine based drugs 
or polychemotherapy regimens may be administered in hopes of curing the patient of 
their disease or improving their survival [6, 8–10]. Many studies have been conducted 
investigating the outcomes of these approaches yielding mixed results when comparing 
overall survival of surgery plus adjuvant therapy with surgery alone [6, 10]. Another 
approach, neoadjuvant therapy, is an option for patients with resectable or locally 
advanced cancer. Neoadjuvant therapy is given before surgery in hopes of downstaging 
the tumor to a point that resection and subsequent adjuvant therapy may be more 
successful [7]. This approach has been shown to improve overall survival between 1.8 
and 10 months depending on tumor classification at the outset [6–9]. Some have 
debated, though, whether the potential benefits of neoadjuvant therapy may be 
outweighed by the risks regarding uncertain tumor histology at the outset as well as the 
possibility of delaying surgery to the point it becomes unfeasible [6, 7]. For patients with 
advanced PC, palliative care aimed at prolonging survival is the main treatment option. 
In September 2013, the FDA approved the addition of nab-paclitaxel to gemcitabine 
chemotherapy regimens for treatment of metastatic PC as the combination increased 
median survival by 1.8 months while having an acceptable toxicity profile [8]. In spite of 
the advances made in PC treatment, overall 5-year survivorship has changed very little 
since 1975 [1]. An 80-85% rate of relapse persists and long term effective solutions for 
advanced disease are largely absent [9]. 
 Because of this, novel chemopreventive strategies aimed at inhibiting the 
advance of PC have become the subject of significant research. Whereas the goal of 
primary prevention is to stop cancer from developing, many studies investigate 
secondary and tertiary prevention techniques focused on being able to “block, retard, or 
reverse the carcinogenic process” [11]. The discovery and development of such 
chemopreventive agents may improve overall survival of PC by reducing aspects of an 
individual’s cancer burden including but not limited to tumor growth and spreading. 
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For centuries, whole foods including fruits, vegetables, and spices have been 
used to prevent and treat a variety of maladies such as wounds, inflammation, and 
infection. More recently, characterization of bioactive agents derived from these whole 
foods have been shown to display anti-microbial, anti-inflammatory, and antioxidant 
effects [12]. Consumption of many of these same foods have also been shown to be 
correlated with reduced cancer risk of various types including those of the colon, breast, 
liver, lung, and pancreas [13–18]. Investigation of the anti-cancer effects of bioactive 
compounds derived from fruits, vegetables, and spices is of great interest as their 
hopeful clinical application may prove a valuable tool in cancer prevention. One 
bioactive compound, diallyl trisulfide (DATS), is derived from Allium vegetables which 
have specifically been shown to be associated with reduced cancer risk of various types 
[19–28]. To date, though, few clinical studies have been completed using DATS. Rather, 
cell based and preclinical studies provide ample evidence that DATS regulates multiple 
cancer hallmark pathways including cell cycle, apoptosis, angiogenesis, invasion, and 
metastasis [29]. DATS has been shown to arrest cancer cells at multiple stages of the cell 
cycle with the G2/M transition arrest being the most widely studied. Induction of G2/M 
arrest via regulation of proteins favoring reduced G2/M passage and transition exit has 
been shown following DATS treatment of multiple cancer types [30]. Additionally, 
increased pro-apoptotic capacity as a result of regulating intrinsic and extrinsic 
apoptotic pathway components has been observed following treatment with DATS [30]. 
Angiogenesis, invasion, and metastasis, three of the largest contributors to cancer 
mortality, represent emerging targets of DATS that support its continued investigation 
as a cancer preventive compound [30]. 
Another pathway associated with cancer progression, the Hedgehog (Hh) 
pathway, lies at the crossroads between aforementioned cancer hallmarks and stem cell 
characteristics including plueripotency, enhanced tumorigenicity, and drug resistance 
[31]. Studies have shown that Hh activity is associated with increased expression of anti-
apoptotic protein Bcl-2, cell cycle progression protein CyclinD1, and angiogenesis 
promoting factor VEGF among many other cancer-associated factors [32]. Additionally, 
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Hh signaling supports stem cell persistence by modulating expression of stemness 
regulators Oct4 and Sox2 [33] as well as drug resistance proteins ABCB1 and ABCG2 [32].  
In one study, it was determined that, of the 24 PC tumors analyzed, each one contained 
mutations in Hh pathway related genes suggesting the Hh pathway plays an important 
role in PC etiology [34]. While the Hh pathway has been shown to be regulated by 
multiple bioactive compounds including sulforaphane from cruciferous vegetables [35, 
36], curcumin from turmeric [37–41], and genistein from soy [37, 42], no studies to date 
have been published examining the effect of DATS on the Hh pathway. Because of this 
gap in scientific knowledge, the role of Hh as a regulator of important cancer related 
pathways, and the apparent importance Hh plays in pancreatic tumorigenesis, we 
investigated the role of DATS in regulating Hh signaling in PC cells. 
Characterization of the Hh pathway was first completed in Drosophila in 1980 
where it was found to regulate polarity and segmentation of the developing embryo 
[43]. In vertebrates, Hh pathway activity is largely limited to embryonic development, 
but has been shown to have a role in pancreas tissue repair in mice [44, 45]. During 
human development, Hh signaling is vital in regulating the formation of limbs, the 
central nervous system, organs of the gastrointestinal tract, and craniofacial structures 
[46–51]. Though the precise mechanisms are yet unknown, the Hh pathway has been 
shown to be aberrantly activated in multiple cancer types, including pancreatic [35, 52–
55]. Increased expression of Hh pathway constituents including Shh, Ptch, Smo, and Gli1 
have been shown in PC tissues compared with normal pancreas tissues [56–58]. 
Furthermore, expression of these constituents is associated with adverse cancer 
outcomes including larger tumor size [58], presence of lymph node metastasis [58], 
advanced TNM stage (a combined measure of primary tumor growth, lymph node 
involvement, and presence of metastases)  [56, 58], and reduced survival [56, 59]. 
A schematic diagram of Hh pathway signaling is presented in Figure 1.1. In 
humans, signal transduction of the Hh pathway begins with synthesis of Hh ligands in 
ligand secreting cells. Sonic Hedgehog (Shh) is the most widely studied Hh ligand in 




Figure 1.1: Schematic diagram of Hh pathway signaling 
 
germ cells and cartilage development respectively [50]. Shh is translated as a 45 
kilodalton (kDa) precursor protein that is auto-proteolitically cleaved into a 26 kDa C-
terminal peptide and a 19 kDa N-terminal peptide (ShhN). The C-terminal fragment 
catalyzes the cleavage and acts in the addition of a cholesterol moiety to the carboxyl 
terminus of ShhN. Further modification of ShhN by Hedgehog acyltransferase (Hhat) 
adds a palmitate group to the amino terminal cysteine. The resulting dually lipidated 
molecule has greatly enhanced signaling activity compared to unlipidated and 
monolipidated ShhN likely due in part to its ability to multimerize on the cell surface 
[60]. Shh release is controlled by the protein Dispatched (Disp) as well as multiple 
members of the a disentigrin and metalloproteinase (ADAM) family including ADAM10 
and ADAM17 [61]. Solubilized Shh travels within the tissue microenvironment and 
interacts with the 12-transmembrane domain receptor protein Patched (Ptch) largely in 
a paracrine fashion. Following ligand-receptor binding, Ptch is ubiquitinated, the 
complex is internalized, and subsequently degraded by the lysozyme [62]. Interaction of 
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Shh with Ptch also releases Ptch-mediated inhibition of the 7-transmembrane domain, 
G-protein coupled receptor protein Smoothened (Smo). A conformational change in 
Smo results in its translocation to the primary cilia where it releases the transcription 
factor Gli1 from suppression by Suppressor of Fused Homolog (SuFu). Gli1 then 
translocates to the nucleus where it binds promoter sequences and enhances 
transcription of downstream targets involved in cell cycle progression, evasion of 
apoptosis, stem cell character, angiogenesis, and epithelial-mesenchymal transition. 
We hypothesized that DATS exerts anti-cancer effects on PC cells by down 
regulating the Hedgehog pathway. We found that treatment of MIAPaCa-2 and BxPC-3 
PC cell lines with DATS resulted in reduced colony formation. Additionally, AsCP-1 cells 
displayed reduced Gli1 mRNA and protein expression following DATS treatment. Protein 
expression of Ptch and Shh were increased upon incubation with DATS. Overexpression 
of Gli1 did not show a significant effect on cell cycle and apoptosis pathways although 
this study require further investigation to better understand how DATS regulates these 
pathway components. But, the observed reduction in expression of pathway effector 
Gli1 suggests that DATS may ultimately inhibit the Hh pathway.
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CHAPTER 2. THE ANTI-CANCER EFFECT OF DIALLYL TRISULFIDE 
2.1 Introduction 
Plants of the Allium genus have long been known to have medicinal qualities. As 
far back as the ancient Chinese in 2700 BC, people have used onions and garlic to 
prevent and treat a variety of ailments [63, 64]. Research has determined that 
organosulfur compounds (OSCs) are the bioactive agents responsible for the observed 
beneficial effects. DATS, the most prominent fat soluble OSC found in garlic, is known to 
regulate disease states including cancer, infection, and metabolic syndrome [65]. Diet 
derived bioactive compounds represent attractive anti-cancer preventive strategies as 
they are generally inexpensive, readily available across the world, and considered to 
have minimal side effects. In recent years, epidemiologic studies have linked 
consumption of Allium vegetables to decreased incidence of cancer. As a result, much 
research in cell culture and animal models has been directed at investigating the precise 
molecular mechanism by which these compounds exert their beneficial effects. Results 
indicate that DATS modulates pathways involved in cancer progression including 
chemical metabolism, cell cycle, apoptosis, angiogenesis, and migration and invasion. To 
date, one study investigating DATS as a clinical intervention for cancer prevention has 
been completed. The following chapter reviews findings of DATS-related cancer 
research and discusses its use as an anti-cancer agent. 
 
2.2 Epidemiological Studies 
In 2007, the World Cancer Research Fund and American Institute for Cancer 
Research reported that garlic “probably” protects against development of colorectal 
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cancer [66]. In support of this claim, multiple meta-analyses and epidemiological studies 
correlate Allium vegetable or garlic intake with reduced risk for myeloma [22] as well as 
gastric [21, 26–28], colorectal [19, 25], endometrial [20], lung [23], and prostate [24] 
cancer. Conversely, there are instances of null findings in some stand-alone cohort 
studies [67, 68] and in cohort specific evaluations of meta-analyses [24, 25]. Two cohort 
studies reporting a null association between garlic intake and colorectal cancer analyzed 
the Nurse’s Health Study, Health Professionals Follow-Up Study, and Cancer Prevention 
Study II Nutrition Cohort [67, 68]. It is worth noting that both used self-administered 
food frequency questionnaires and considered a serving of garlic as one clove or 4 
shakes of garlic powder or garlic salt [67, 68]. The reported use of garlic powder and 
garlic salt within these studies is not disclosed, but it is possible that use of these 
ingredients accounted for intake without providing the same protective effect as fresh 
garlic cloves [67, 69]. The use of mailed food frequency questionnaires may also partially 
explain the null findings observed in the aforementioned cohort studies. Results of one 
meta-analysis of Allium vegetable intake and prostate cancer risk reported more 
significant risk reductions in studies utilizing face-to-face interviews with nutrition 
experts (odds ratio (OR)=0.70, 95% confidence interval (CI): 0.59-0.84) compared with 
those using self-administered food frequency surveys (OR=0.89, 95% CI: 0.78-1.02) [24]. 
Likewise, a case-control study employing face-to-face interviews indicated risk ratios of 
0.92 (95% CI: 0.79-1.08) and 0.56 (95% CI: 0.44-0.72) for lung cancer corresponding to 
raw garlic consumption <2 times/week and ≥2 times/week respectively compared to 
individuals who never consumed raw garlic [23]. 
  Consuming 20g of Allium vegetables per day is associated with an OR of 0.91 (95% 
CI: 0.88-0.94) for gastric cancer [21]. Comparing highest and lowest garlic intakes, two 
recent meta-analyses reported a risk ratio of 0.49 (95% CI: 0.38-0.62) for gastric cancer 
[27] and 0.85 (95% CI: 0.72-1.00) for colorectal cancer [25]. In one meta-analysis, high 
and low intake were gauged on such diverse measures as yearly, weekly, and daily 
consumption as well as subject-assessed ratings of “high” or “low” [27]. Such disparity in 
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intake quantification may partially explain the mixed results of previously mentioned 
epidemiological studies. Cultural and ethnic differences must also be considered. 
Greater risk reduction associated with garlic intake was observed in Asian and South 
American populations than in European populations in some studies [24, 27] while 
similar results across continents were observed in another investigation of total Allium 
vegetable intake [21]. The potential protective effect of garlic supplementation has also 
been studied. Similar to Allium vegetable intake, data regarding garlic supplementation 
use have shown an inverse association with cancer risk (hazard ratio = 0.55, 95% CI: 
0.34-0.87) when comparing high use (≥4 times per week) with non-users [70] as well as 
null results [67, 68, 71]. Little description is given about the type of garlic supplement 
used (powder, aged garlic extract, etc.) which may explain the mixed findings. 
 
2.3 Synthesis, Metabolism, and Pharmacokinetics 
Fresh garlic contains a mixture of water, fiber, carbohydrates, protein, and fat as 
well as more than 20 vitamins and minerals and at least 33 sulfur containing compounds 
[72, 73]. One of the primary precursors of OSCs in garlic is γ-glutamyl-S-alk(en)yl-L-
cysteine [69] (Figure 2.1). Within the garlic clove, this compound is hydrolyzed and 
oxidized into S-alk(en)yl-L-cysteine sulfoxide (alliin) which accumulates naturally during 
storage at cool temperatures [63, 69]. Processing garlic by cutting or chewing ruptures 
vacuoles containing alliinase [63, 69]. This enzyme converts alliin to allicin and other 
thiosulfinates responsible for the odiferous nature of garlic [63, 69]. The allicin yield is 
about 2.5mg/g of garlic which correlates to 5-20mg per clove [72]. Allicin quickly 
decomposes into products including diallyl sulfide, diallyl disulfide, and DATS with yields 
of 30-100, 530-610, and 900-1100 μg/g respectively [69, 72]. 
In pharmacokinetic studies, DATS was shown to be 99% absorbed in rabbits [74] 
while its precursor, allicin, was 79% absorbed in animals within 30-60 minutes [75]. 
Following ingestion of 730 μmol of DATS in human subjects, breath acetone increased 
reaching a maximum at around 20 hours [76]. Allyl methyl sulfide, a known component 
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of breath and putative breakdown product of OSCs, was also increased reaching 
maximum concentration around the 5 hour time point [76]. While the precise 
mechanism of DATS metabolism remain elusive, these data suggest DATS is rapidly 
metabolized but not before causing acetone production to increase by some unknown 
mechanism. No pharmacokinetic studies in humans have been able to detect DATS in 
urine or plasma following garlic ingestion. Following a 10 mg dose of DATS into the 
jugular vein of rats, though, DATS plasma concentration peaked at 5.5 μg/mL (31 μM) 
within 1 minute followed by a steady return to baseline levels within 24 hours  [77]. 
Using a microemulsion intravenous injection technique in rats to deliver 30 mg/kg DATS, 
plasma concentration peaked at 7.06 μg/mL (40 μM) within 3 hours [78]. Compared to 
the current technique of using Tween 80 to emulsify DATS, microemulsion resulted in a 
slower clearance rate possibly because of delayed penetration and distribution to  









Alliinase (released by cutting or chewing) 
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tissues [78]. Using intravenous doses of DATS avoids the first pass effect of the liver 
which may explain why researchers were able to detect plasma DATS in these studies. 
Future pharmacokinetic studies of DATS are vital for its investigation as a 
chemopreventive agent. Understanding achievable concentrations following 
intravenous dose as well as oral ingestion are paramount. In order to achieve accurate 
results, compound stability must also be considered. Researchers have shown that 
stability of DATS in rat blood is influenced by purification technique, storage 
temperature as well as duration, and freeze-thaw cycles [77]. 
No focused metabolic studies in humans using DATS have been published at this 
time. Recently, DATS was shown to directly interact with the antioxidant response axis 
by reacting with the Nrf2 regulator Keap1 [79]. Multiple cysteine residues of β-tubulin 
are also targeted by DATS with implications in microtubule polymerization [80]. The 
pharmacokinetics of DATS are poorly understood as multiple metabolic studies have 
instead focused on SAC, another OSC derived from garlic [81]. As is the case with many 
bioactive metabolites, it is believed that the kidneys as well as the liver participate in 
conjugation reactions with DATS resulting in excretion, reabsorption, or further 
metabolism  [82]. In order to effectively study anti-cancer mechanisms in a clinical 
setting, DATS-specific metabolic and pharmacokinetic studies should be a focus of 
future research. 
 
2.4 In vitro Mechanism of Action 
Much of the past and current research into the DATS mechanism of action 
concerns induction of cell cycle arrest, increased programmed cell death, inhibition of 
migration and invasion, and reduced angiogenesis. The results of many in vitro studies 
utilizing DATS are summarized in Table 2.1. A schematic of in vitro and in vivo molecular 
mechanisms are depicted in Figure 2.2. 
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2.4.1 In Vitro Cell Cycle Arrest 
Dysregulation of important cell cycle regulatory mechanisms is an initiating 
event in cancer development allowing for uncontrolled cell cycle progression and rapid 
tumor growth. A common theme in re-gaining proper cell cycle regulation is maintaining 
normal levels of active cyclins, cyclin dependent kinases, and regulatory units that act on 
these proteins. Many have shown DATS to induce G2/M arrest [80, 83–100] and further 
elucidation of the precise molecular mechanisms involved in cell cycle blockade provides 
additional support for the anti-cancer role of DATS. 
DATS has been shown to induce cell cycle arrest by enhancing generation of 
reactive oxygen species (ROS) [87, 88, 97, 99, 101]. One pathway of  ROS generation 
begins with degradation of the iron storage protein ferritin which has been shown 
following DATS treatment leading to an increase in labile iron pool (LIP) size [97, 101, 
102]. Then, through the Fenton/Haber-Weiss reaction, free ferric iron reacts with 
superoxide and hydrogen peroxide to form hydroxyl radicals and hydroxide ions [88, 
103]. These and other ROS are involved in biological processes such as DNA damage and 
cell death signal transduction [103]. ROS induced DNA damage may explain the rapid 
phosphorylation and activation of the DNA damage sensing protein Chk1 [93]. In Chk1 
expressing prostate cancer cells, DATS induced accumulation of CyclinB1, securin, and 
serine 10 phosphorylated Histone H3 (p-H3) corresponding to mitotic arrest [93]. Cells 
expressing wild type ataxia telangiectasia and Rad3 related (ATR), another DNA damage 
sensing protein, showed similar accumulation [89]. Prostate and colon cancer cells 
displayed less accumulation of these targets following Chk1 knockdown and expression 
of inactive ATR respectively [89, 93]. Together, these data suggest accumulation of cells 
in G2/M may be partially dependent on DNA damage checkpoint proteins Chk1 and ATR 
[89, 93]. 
DATS treatment has been shown to regulate downstream targets of another 
DNA damage sensing protein, p53, including Cdc25C, Cdk1, and Wee1 [85, 87, 88, 92–94, 
96]. These proteins are well characterized cell cycle regulators further supporting the 
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idea that DATS induces cell cycle arrest through inducing DNA damage. Cdc25C, a 
regulatory phosphatase that promotes passage into mitosis, has been well characterized 
by multiple investigators [94, 104]. The reduced Cdc25C protein levels triggered by DATS 
were reversed with antioxidant pre-treatment suggesting oxidative stress may account 
for decreased expression [88, 94]. This finding is consistent with data indicating that 
oxidation of cysteine residues at amino acids 330 and 377 negatively impacted Cdc25C 
stability [104]. In contrast to these findings, overexpression of wild type Cdc25C as well 
as expression of protein mutated at key cysteine residues failed to rescue prostate 
cancer cells from DATS-induced G2/M arrest suggesting a dispensable role of Cdc25C in 
this model [94]. 
DATS-mediated arrest specifically during passage into mitosis has been examined 
by several investigators [80, 85, 87, 89, 92–94, 96, 100, 105, 106]. During the G2/M 
transition, Cdc25C mediated dephosphorylation of Cdk1 and ensuing Cdk1/CyclinB1 
complex formation promote entrance into mitosis as a result of enhanced kinase activity. 
Although DATS prompted an increase in CyclinB1 protein, treatment also reduced 
Cdc25C expression and increased levels of tyrosine 15 phosphorylated Cdk1 leading to 
inactivation of the Cdk1/CyclinB1 complex [80, 85, 87, 89, 92, 93, 96, 100, 105, 106]. 
Without adequate levels of Cdk1 and CyclinB1 co-localized in the nucleus, cells are 
unable to move past the G2/M checkpoint.  Following the start of DATS treatment, 
CyclinB1 appeared in the nucleus within 1 hour while Cdk1 was not observed in the 
nucleus until between hours 2 and 4 [94]. These findings may clarify the transient nature 
of G2/M arrest as cells eventually regained Cdk1/CyclinB1 complex kinase activity after 
8 hours of DATS treatment [94]. Interestingly, a small percentage of treated cells have 
even shown the ability to escape G2/M arrest during 24 hours of continuous DATS 
treatment [94]. Another group detailed gradual return to normal cell cycling following 
cessation of a 12 hour DATS treatment [90]. Based on these findings, future research 
directions in cell cycle regulation need to focus on clarifying specific time points at 
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which a DATS treatment regimen may achieve maximum arrest specifically in G2/M 
phase. 
Mitotic exit is dependent on an active anaphase promoting complex (APC) made 
up of Cdc27, Cdc20, and Cdh1 subunits [93]. DATS promoted inactivation of Cdc27 and 
Cdh1 by maintenance of phosphorylation [89, 93]. Similarly, phosphorylated Cdh1 and 
Cdc20 were more prevalent in ATR wild type cells than in cells expressing inactive ATR 
[89]. The APC substrate securin, which must be degraded for sister chromatids to 
separate, was increased following DATS incubation [89, 93]. This is thought to be a 
result of decreased APC activity rather than up regulation of securin protein [89, 93]. 
After DATS treatment, staining of α-tubulin showed fluorescence exclusively 
surrounding the nucleus rather than throughout the whole cell as observed in control 
cells [87, 93]. This data agrees with the finding that DATS disrupted the microtubule 
network in colon cancer cells [80, 90]. Researchers observed depolymerization of the 
microtubule network as a result of oxidative modification of cysteine residues in β-
tubulin [80]. Taken together, these results suggest DATS may also induce G2/M arrest by 
reducing the ability of chromosomes to separate during the mitotic phase of the cell 
cycle. 
While multiple reports indicate no change in the fraction of S phase arrested 
cells [105, 106], evidence exists supporting both increased [105, 107, 108] and 
decreased [87, 92, 93, 106] G0/G1 fractions following DATS treatment. Cell line specific 
and technique differences may account for these discrepancies as treatment dose as 
well as duration play important roles in cell cycle regulation. In PC cells, DATS was 
shown to have an inhibitory effect on cell cycle progression protein CyclinD1 while 
simultaneously enhancing protein levels of the Cdk inhibitor CDKN1A (p21Cip1/Waf1) [106, 
109]. These results corroborate results in prostate [87] and breast [105, 110] cancers 




2.4.2 Induction of Programmed Cell Death 
Various mechanisms exist to protect cells from unrestricted growth. In cancer 
cells, these mechanisms are dysregulated leading to rapid tumor progression. Enhancing 
programmed cell death is a promising anti-cancer strategy aimed at reducing tumor 
advance. Apoptotic processes are divided between caspase-dependent and caspase-
independent pathways. Caspase dependent mechanisms can be further separated into 
intrinsic (mitochondria mediated) and extrinsic (death receptor mediated) processes. A 
growing body of evidence suggests that DATS acts by prompting cancer cells to obey cell 
death signals including DNA damage, oxidative stress, and cellular damage. 
In addition to its role in cell cycle arrest, ROS generation is known to induce cell 
death [91, 96, 111–115]. As mentioned previously, ferritin degradation and subsequent 
increased LIP size is one mechanism by which ROS are generated following DATS 
treatment. Augmented expression of p66Shc and Itch E3 ligase induced by DATS are part 
of the mechanism by which ferritin is degraded [97, 101, 102, 116]. These proteins are 
further implicated in cell death signal propagation as their reduced wild type expression 
resulted in resistance to the effects of DATS [97, 102]. The role of LIP size in DATS-
mediated cell death recently came into question by the finding that iron chelation 
afforded no protection from DATS-induced cytotoxicity [102]. Further research is 
required to characterize the role of iron in cancer cells as high iron status may have a 
substantial impact on promoting neoplastic progression [117]. 
Results across many cancer cell types have observed activation of the intrinsic 
apoptotic pathway following DATS treatment. Increased activation of the apoptosis 
regulating protein JNK has been shown across many studies after DATS incubation [91, 
111, 114, 118–121]. One cause of JNK activation may be related to generation of 
another potent ROS, hydrogen peroxide. Under non-stress conditions the JNK activator 
ASK1 is held inactive by the ubiquitous redox sensing proteins Thioredoxin (TRX) and 
Glutaredoxin (GRX). Certain stressors promote oxidation of the intermolecular disulfide 
bond between TRX and GRX causing dissociation and subsequent activation of ASK1. 
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Enhanced ASK1 dissociation in addition to JNK phosphorylation following DATS 
treatment were recently observed in breast cancer cells [120]. Furthermore, ASK1 
activation was inhibited following catalase transfection implicating DATS-induced 
production of hydrogen peroxide as the putative source of TRX:GRX bond oxidation 
[120]. 
Increased expression of p53 has been shown to have pro-apoptotic action in 
pancreatic [106], lung [91], breast [105], and skin [96, 99] cancer cells. DATS treatment 
increased nuclear translocation of p53 in breast and PC cells and decreased expression 
of MDM2, a negative regulator of p53 [105, 106]. Downstream targets of p53 include 
members of the Bcl-2 family of proteins involved in regulating intrinsic apoptosis [122]. 
Thus, DATS treatment is known to increase apoptosis by regulating expression of pro-
apoptotic Bax [92, 95, 98–100, 105, 106, 113, 115, 121, 123–125], Bak [92, 112, 115, 
123], Bid [92], Bad [114], PUMA [123, 125], and NOXA [123] as well as anti-apoptotic 
Bcl-2 [91, 92, 95, 98, 99, 105, 106, 112–114, 119, 121, 123–127] and Bcl-XL [92, 99, 112, 
121, 123, 127]. Moreover, the pro-apoptotic protein Bim, which is a downstream target 
of JNK, displayed increased phosphorylation following DATS incubation thus clarifying 
one connection between DATS treatment, ROS generation, and induction of apoptosis 
[120, 123]. It is noteworthy that, although Bcl-2 overexpression did not provide 
protection from DATS-induced apoptosis in one prostate cancer cell line, Bax and Bak 
knockdown conferred partial resistance [92, 112]. These data suggest DATS-mediated 
apoptosis may be attributed to enhanced pro-apoptotic action of Bax and Bak rather 
than to reduced anti-apoptotic activity of Bcl-2 and Bcl-XL. Results show that enhanced 
apoptotic action may be brought about by translocation of pro-apoptotic proteins to the 
mitochondrial membrane due to disruption of the interaction with Bcl-2 [99, 119] and 
decreased interaction with 14-3-3 proteins [128]. 
Localization of pro-apoptotic proteins to the mitochondrial membrane leads to 
mitochondrial membrane depolarization [91, 96, 99, 129, 111–114, 121, 123], calcium 
release from the endoplasmic reticulum [96, 99, 111, 130], and mitochondrial release of 
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various apoptosis regulating proteins. Results investigating apoptosis inhibitors 
consistently support the decrease of XIAP expression [100, 121, 123, 131] following 
DATS treatment, but cell specific discrepancies exist regarding regulation of cIAP [121, 
123, 131] and survivin [91, 123, 131]. Release of Smac [111] and expression of HtrA2 [96, 
99] have been shown to be up regulated following DATS treatment signifying reduced 
inhibition of cell death. Following release from the mitochondria, cytochrome C is 
known to complex with Apaf-1 to initiate cleavage of pro-caspase-9 thus activating 
caspase-dependent apoptosis through executioner caspase-3. Reports of enhanced 
cytochrome C release [84, 99, 111–113, 121, 123, 124, 127], increased Apaf-1 
protein[99], enhanced caspase-9 expression and activity [96, 99, 121, 123, 124, 127], 
and greater cleaved PARP [92, 95, 96, 99, 114, 121, 127, 128] further support the 
extensive pro-apoptotic capabilities of DATS. Many pro-apoptotic effects have been 
shown to be partially abolished following superoxide dismutase overexpression [115] or 
pre-treatment with an antioxidant such as N-acetylcysteine [91, 99, 112, 114] suggesting 
they are ROS dependent. 
In addition to the intrinsic apoptotic mechanism, DATS is known to affect the 
extrinsic apoptosis pathway. Extrinsic apoptosis is initiated through binding of an 
extracellular death ligand such as TRAIL or Fas to a death receptor (DR) on the cell 
membrane. The subsequent signaling cascade results in caspase-8 activation which also 
activates caspase-3. It is well established that LNCaP prostate cancer cells are resistant 
to TRAIL-induced apoptosis while PC-3 cells are TRAIL sensitive [123]. DATS treatment 
was able to sensitize LNCaP cells to TRAIL induced apoptosis and synergize with TRAIL to 
enhance apoptosis in PC-3 [123]. Greater expression of extrinsic pathway constituents 
such as DRs as well as their ligands has been observed in other cancer types following 
DATS treatment [91, 105, 106, 121]. Additionally, downstream events including 
increased expression and activity of caspase-8 [121, 123, 124, 132] and caspase-3 [80, 




Components of the endoplasmic reticulum stress-mediated apoptosis pathway 
including BiP, CHOP, and caspase-4 were shown to be increased in one study following 
DATS treatment [99]. Addition of a caspase inhibitor did not completely reverse the 
effects of DATS in a basal cell carcinoma model implying apoptotic action also occurs 
through caspase independent pathways [99]. In support of this hypothesis, researchers 
observed increased nuclear levels of DNA fragmentation proteins AIF and EndoG [99]. 
Autophagy, another caspase independent pathway with potential for causing cell death, 
has been studied following treatment with DATS precursor allicin, but not with DATS 
itself [129]. Understanding the cross-talk with apoptosis as well as the prospect of 
characterizing the dual nature of autophagy necessitate further autophagy-focused 
research in cancer cell lines following treatment with DATS. 
Results from in vitro studies have shown DATS to be more potent at reducing cell 
viability and proliferation than other OSCs including diallyl disulfide and diallyl sulfide 
[92, 96, 114, 130, 133–135]. Investigation of nine trisulfides found those with three 
carbon chains provided the most inhibition of cell viability compared to compounds with 
longer chains [136]. Similar experiments ordered the efficacy of trisulfides at inducing 
apoptosis as follows: bis(2-methylallyl) trisulfide > DATS ≈ dibutenyl trisulfide ≈ 
dipentenyl trisulfide [98]. It is important to note that DATS is considered minimally toxic 
to non-transformed cells at concentrations as high as 160 μM [87, 92, 101, 112, 115, 
130]. Though some levels of ROS were generated in the normal breast epithelial cell line 
MCF-10A following DATS incubation, Bax and Bak expression as well as apoptotic figures 
remained unchanged [115]. While these data provide an explanation for how MCF-10A 
cells avoid apoptosis, mechanistic studies may help to elucidate how these cells avoid 
altering apoptosis-related gene expression in spite of ROS production. Such research 
may provide insight into how transformed cells evade apoptosis during cancer 
progression and promote understanding of the mechanisms by which normal cells are 




2.4.3 Inhibition of Migration and Invasion 
Cancer spreading is a result of migration events leading to tumor growth in new 
areas of organs as well as invasion events leading to growth in other tissues. It is well 
understood that the spreading of cancer throughout the body is a major cause of 
mortality. Furthermore, a cancer diagnosis in late stages, after spreading has occurred, 
represents up to a 13.5 fold decrease in survival compared to diagnosis during early, 
localized stages [1]. These statistics make apparent the need for anti-cancer strategies 
aimed at reducing migration and invasion. 
Recent in vitro work has revealed inhibition of migration and invasion proteins 
following DATS treatment. Expression and activity of MMP -2, -7, and -9 were inhibited 
indicating decreased ability to degrade basement membranes [107, 133, 134, 137, 138]. 
Known inhibitors of MMPs, TIMP-1 and -2, were increased upon DATS treatment leading 
to enhanced tight junction formation between bladder cancer cells [137]. In this report, 
claudin expression was shown to decrease following DATS treatment [137]. Expression 
of different claudins and their relation to an invasive phenotype are highly contextual as 
lines of evidence exist claiming claudins both promote [139] and inhibit [140, 141] 
migration, invasion, and metastasis. These results necessitate further research to 
elucidate the cell-specific relationship between claudin expression and overall 
invasiveness characterization. Specific upstream metastasis-related proteins were 
reduced following DATS treatment including iNOS, Grb2, Ras, COX-2, PI3-K, JNK1/2, and 
p38 [133, 138]. While enhanced JNK1/2 expression was shown to be responsible for 
apoptosis induction [91, 114, 119, 120], others have shown JNK2 to enhance cell 
migration [142]. Further research is required to better characterize this apparent 
dichotomy. Cell surface proteins vimentin and E-cadherin, which are also known to be 
involved in the epithelial-mesenchymal transition, were regulated following DATS 
treatment to favor increased adhesion [115]. Regulation of the JAK/STAT pathway may 
also contribute to migration and invasion of cancer cells as ectopic expression of STAT3 
in LNCaP cells resulted in enhanced migration [143]. DATS treatment reduced migration 
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by blocking STAT3 phosphorylation events related to dimerization and nuclear 
localization [143]. 
 
2.4.4 Reduced Angiogenesis 
Because cell culture models contain no vasculature, in vitro investigation of 
angiogenesis often examines protein levels of angiogenesis proteins as well as the effect 
of treatment on angiogenesis model systems. VEGF secretion is responsible for 
increasing size, number, and penetrance of tumor vasculature required for each 
incremental increase in tumor size [138]. DATS treatment has been shown to reduce 
expression and secretion of VEGF as well as multiple upstream angiogenesis proteins in 
different cancer cell types [107, 138]. Human umbilical vein endothelial cells treated 
with DATS also demonstrated decreased VEGF secretion, decreased capillary-like tube 
formation, and reduced VEGF receptor expression [138, 144]. Incubating these 
endothelial cells with conditioned media from DATS treated osteosarcoma cells also 
resulted in decreased capillary-like tube formation compared to incubation with media 
from untreated cells [107]. It was shown that these effects were not caused by DATS 
presence in the media but rather by the presence or absence of secreted factors within 
the conditioned media [107]. 
 
2.4.5 Interaction with Hormone Regulated Cancer Types 
Hormone signaling by estrogen and androgens are known to be key factors in 
progression of breast and prostate cancers respectively [110, 145]. Regulation of 
hormone related signaling in these cancer types not only displays the diverse effects of 
DATS but provides further evidence that DATS may be a useful anti-cancer agent. In 
breast cancer, estrogen sensitivity and HER-2 expression are important factors in patient 
prognosis. Recent research involving breast cancer cell lines differing in estrogen 
sensitivity and HER-2 status showed diminished cell viability upon DATS treatment [110, 
115]. The observed reduction in cell viability was unaltered following ER-α 
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overexpression in the triple negative breast cancer cell line MDA-MB-231 [110]. These 
data implicate DATS as an attractive anti-cancer agent because of its broad ability to 
decrease cell viability in breast cancer cells regardless of ER-α and HER-2 status. DATS 
treatment also reduced estrogen receptor mRNA, protein levels, and reporter activity in 
ER-α positive breast cancer cell lines MCF-7 and T47D [110]. 
In prostate cancer, the effect of androgen dependence has been investigated by 
comparing the effect of DATS in androgen independent PC-3 and androgen dependent 
LNCaP cell lines. Both underwent significant apoptosis following DATS treatment [112, 
119]. Upon Bcl-2 overexpression, PC-3 cells were protected from apoptosis [119] while 
apoptosis was unchanged in androgen sensitive LNCaP cells [112]. These data suggest 
DATS may be an effective anti-cancer agent in prostate cancer but implies a differential 
role of the androgen receptor in regulating apoptosis. DATS also reduced androgen 
receptor mRNA level, protein level, transcriptional activity, and PSA secretion in 
prostate cancer cells [145]. Furthermore, DATS reversed androgen receptor nuclear 
translocation and cell proliferation induced by the androgen analog R1881 [145]. 
 
2.4.6 Other Mechanisms 
Regulation of cellular responses to stressors has long been considered an 
important anti-cancer mechanism. Enhanced mRNA levels of phase II detoxifying 
enzymes NADPH:quinone oxireductase and heme oxygenase were observed following 
DATS treatment of various cancer cells [79, 118, 146]. Induction of phase II enzymes is a 
desirable goal especially in preventing cancer initiating events as cells are able to better 
inactivate and remove mutation causing carcinogens [147]. The stress-sensing protein 
Nrf2 and the antioxidant response axis may be partially responsible for this observed 
effect. In one study, Nrf2 expression was positively correlated with expression of 
multiple phase II genes [118] while another study observed reversal of phase II gene 
induction in DATS treated cells transfected with Nrf2 siRNA [79]. Under non-stress 
conditions, Nrf2 is degraded in the cytoplasm through interaction with Keap1. 
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Introduction of stressors modifies cysteine residues on Keap1 resulting in Nrf2 
accumulation, translocation to the nucleus, and induction of downstream targets. 
Increased Nrf2 protein levels and augmented antioxidant response element activity 
have been observed in liver cancer cells following DATS treatment [118]. In fact, DATS 
may directly be involved in Nrf2 signaling as the mass of a mono-allyl sulfide moiety was 
recently observed bound to the protein fragment containing cysteine 288 of Keap1 
following DATS treatment of gastric cancer cells [79]. This amino acid was shown to be 
necessary for regulating Nrf2 activity as a mutation resulted in failed induction of target 
genes [79]. Determining the interaction of DATS with specific transcription factors and 
their regulators by mass spectrometry represents an exciting area of research as it may 
provide a direct link between DATS treatment and its downstream effects. The anti-
cancer role of DATS may also extend into sensitizing cancer cells to chemotherapy. 
Differential effects of DATS on drug resistance proteins observed in multiple reports 
indicate a need for continued research to define these molecular mechanisms [73, 148]. 
Altered cellular signaling of key pathways involved in growth, differentiation, and 
development exemplify the breadth of mechanisms affected by DATS. Inhibition of the 
mTOR, NF-κB, and MAPK cascades provide further evidence that DATS limits the survival 
capacity of cancer cells [79, 91, 95, 97, 100, 101, 105, 106, 114, 116, 119, 121, 128, 133, 
134]. HDAC inhibition as well as increased acetylation of the promoter for IκB-α 
regulator MT2A in gastric cancer cells provides one mechanism by which DATS may 
regulate NF-κB [100]. The Notch developmental and stem cell related pathway has also 
been shown to be affected by DATS in osteosarcoma cells [107]. Decreased levels of 
transcriptional activator proteins such as Notch-1 intracellular domain, Hes, and Hey 
were observed upon DATS incubation along with reduced downstream expression of 
CyclinD1 [107]. In the same study, researchers observed increased expression of miR-
143 and miR-145 along with decreased expression of miR-21 [107]. In another stem cell 
related study, DATS reduced the CD44high/CD24low/ESA+ population as well as ALDH 
activity in breast cancer cells [135]. Researchers proposed that reduced FoxQ1 protein 
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expression as a result of DATS treatment caused this effect as well as the observed 
reduction in mammosphere growth, induction of apoptosis, and modulation of cell cycle 
regulatory proteins [135]. Further investigation is required in these emerging areas of 
cancer research to characterize the roles of epigenetics, developmental and stem cell 
pathways, and miRNAs as well as their response to anti-cancer agents. 
 
2.5 In Vivo Mechanism of Action 
Because of the ability to more adequately re-create a tumor specific 
microenvironment, examine tumors as they relate to whole organisms, and relate 
results to the endpoint of survival, in vivo models are a desirable next step in cancer 
research following in vitro studies. Common pathways affected are often similar to in 
vitro experiments and results act as rationale for potential future human studies. A 
summary of in vivo results is shown in Table 2.2. 
 
2.5.1 Prevention of Chemical Carcinogenesis 
Reduction of chemical related carcinogenesis was among the first anti-cancer 
strategies investigated using DATS and this has been reviewed by others [30, 149]. 
Briefly, experiments investigating the activity of chemical metabolizing enzymes in mice 
following DATS incubation display suppression of phase I enzymes responsible for 
activation of chemical carcinogens and induction of phase II enzymes responsible for 
detoxification [150]. Recently, DATS was shown to induce phase II enzymes 
NADPH:quinone oxireductase and heme oxygenase in the stomach of mice [79]. 
Additionally, Nrf2 was shown to be indispensable for DATS-mediated phase II enzyme 
induction as Nrf-/- and Nrf2 siRNA transfected cells from mouse embryos showed 




2.5.2 Reduced Tumor Growth and Increased Apoptosis 
Many results from in vivo studies of various cancer models detail decreased 
tumor volumes as well as lower tumor incidence and multiplicity following DATS 
treatment [100, 114, 123, 124, 131, 135, 138, 148, 151–153]. The DNA binding ability of 
mitogenic transcription factor AP-1 and activity of cell survival pathway constituent Akt 
were shown to be reduced following DATS treatment [151]. Additional regulation of c-
Myc, phosphorylated mTOR, TNF-α, IL-6, IKK, IκB-α, and NFκB expression observed in 
multiple models correspond to additional inhibition of growth signaling and survival 
pathways as a result of DATS treatment [100, 123, 151, 154]. Topical application of 25 
μM DATS prior to application of a carcinogen was shown to attenuate expression of 
cancer progression marker COX-2 [151]. These results support the idea that DATS may 
serve as useful anti-cancer agents in vivo by reducing cancer progression. 
Subcutaneous glioblastoma tumors displayed enhanced apoptotic activity 
through reduced Bcl-2 expression, increased Bax protein levels, and greater caspase-3 
activation [153]. DATS treatment of orthotopically implanted prostate cancer cells in 
nude mice revealed an increased pro-apoptotic:anti-apoptotic signal ratio by 
modulation of Bax, Bak, Bcl-2, and Bcl-XL along with greater DR protein levels [123]. 
Further regulation was observed with TRAIL co-treatment demonstrating the interplay 
between caspase-dependent mechanisms [123] In a TRAMP model of prostate cancer, 
decreased XIAP protein along with increased survivin have been documented following 
DATS administration [131]. 
While hematopoietic cancers do not display solid tumors, reduced cancer 
progression was evident following DATS treatment of nude mice intraperitoneally 
injected with murine leukemia cells [108]. Enhanced phagocytic activity and natural 
killer cell cytotoxicity were observed in DATS treated mice following 10 mg/kg treatment 
for 14 days [108]. In cancer bearing mice, B-cell proliferation was reduced with DATS 
treatment [108]. Non-leukemic mice showed no change in phagocytosis or B-cell 
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proliferation representing another instance of the relative innocuous nature of DATS 
toward un-transformed cell types [108]. 
 
2.5.3 In Vivo Cell Cycle Arrest 
Increased cell cycle arrest following DATS treatment was recently connected to 
reduced histone deacetylase activity and enhanced histone H3 and H4 acetylation [153]. 
Persistent acetylation surrounding negative regulators of the cell cycle may diminish 
checkpoint passage thereby inhibiting cell cycle progression [153]. Enhanced p53 
expression, MDM-2 degradation, reduced Cdc25C, increased CDKN1A (p21Cip1/Waf1), and 
greater phosphorylated Cdk1 induced G2/M arrest following 1 week of DATS treatment 
of glioblastoma tumors [153]. Increased CyclinB1 and securin protein are viable 
downstream endpoints that further support a large body of evidence suggesting DATS 
promotes cell cycle arrest in vivo [100, 154]. 
 
2.5.4 Inhibition of Migration, Invasion, and Angiogenesis 
In vivo models allow investigators to study migration, invasion, and angiogenesis 
more completely. A recent publication detailed reduced angiogenesis in chick embryos 
following DATS treatment supplemented with VEGF [138]. This supports prior findings 
that 4 weeks of daily 40 mg/kg DATS decreased microvessel density along with VEGF 
and IL-6 expression [123]. In a glioblastoma xenograft model, VEGF expression was 
reduced following 7 days of DATS treatment [153]. Decreased hemoglobin 
concentration in tumor sections was observed in colon cancer xenograft and allograft 
models treated with 50 mg/kg DATS suggesting anti-angiogenic action [138, 152]. 
However, a 2 mg/kg DATS treatment of TRAMP mice did not decrease number of vessels, 
diameter of vessels, or expression of angiogenesis marker CD31 [154]. These results 
indicate that, while DATS treatment may directly influence angiogenesis in some studies, 
dosage must be considered. 
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Decreased expression of MMP-2, -7, and -9 as well as p-STAT3 were observed in 
a mouse models supporting the role of DATS as an inhibitor of migration and invasion 
[123, 143]. Enhanced differentiation represents an exciting anti-cancer prospect of DATS 
treatment as cells with an undifferentiated phenotype are often responsible for invasion, 
migration, and metastasis. Investigators observed a decreased incidence of poorly 
differentiated prostate carcinoma in dorsolateral prostates of 1 mg and 2 mg DATS 
treated mice [154]. Increased area of well differentiated carcinoma and prostatic 
intraepithelial neoplasm were also observed [154]. These data suggest DATS may be 
able to inhibit the transformation from a well differentiated to poorly differentiated 
phenotype and reduce lung and lymph node metastases [154]. In a zebrafish model, 
DATS treatment decreased the number of metastatic foci as well as maximal metastatic 
distance of triple negative breast cancer cells [134]. 
 
2.6 Clinical Studies 
Multiple human trials have been undertaken investigating the anti-cancer 
capacities of garlic-derived compounds [155–160], but only one clinical study has 
specifically examined the anti-cancer role of DATS [161]. Researchers administered 200 
mg synthetic DATS daily along with 100μg selenium every other day for 1 month per 
year for 3 years in a Chinese population at moderate to high risk for developing gastric 
cancer based on presence of stomach disorders, family history of cancer, or lifestyle 
factors such as smoking or alcohol consumption [161]. In the first 5 years of follow-up, 
the relative risk in the intervention group was 0.67 (95% CI: 0.43 – 1.03) for malignant 
tumors and 0.48 (95% CI: 0.21 – 1.06) for gastric cancer [161]. The intervention reduced 
morbidity of all cancers by 22% and reduced gastric cancer morbidity by 47% [161]. 
Following adjustment for factors including family history of cancer, alcohol consumption, 
and age, the relative risk associated with the DATS intervention reached significance for 
malignant tumors (relative risk = 0.51 (95% CI: 0.30 – 0.85)) and gastric cancer (relative 
risk = 0.36 (95% CI: 0.14 – 0.92)) in men only. Researchers also report this dose of 
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synthetic DATS was well tolerated. The results of this trial indicate a need for future 
clinical trials investigating the effects of garlic-derived bioactive compounds, specifically 
DATS. Dose, duration, cancer type, and cancer stage must also be selectively studied to 
determine the anti-cancer efficacy of DATS. 
 
2.7 Conclusions 
Accumulating evidence has shown DATS to regulate many cancer-related 
pathways including but not limited to chemical detoxification, cell cycle arrest, cell 
death, inhibition of invasion and migration, and reduced angiogenesis. Epidemiological 
studies provide background support for the beneficial health properties of garlic that 
humans have known for centuries by correlating Allium vegetable intake with reduced 
cancer risk. Many similar outcomes from cell based and preclinical models detail the 
molecular mechanisms involved in the anti-cancer effects of DATS as well as provide 
rationale for further investigation. Additionally, the limited use of garlic compounds in 
clinical cancer research has yielded enough positive data to warrant continued 
exploration. Similar anti-cancer properties observed in experiments utilizing other diet-
derived compounds such as curcumin, sulforaphane, and resveratrol emphasize the 
potential usefulness of diet in reducing cancer progression [162]. As such, continued 
elucidation of established and novel molecular mechanisms regulated by DATS must be 
completed. While all levels of research must be sustained, emphasis of future studies 
should focus on DATS-related pharmacokinetics and metabolism to better support the 








Table 2.1: Summary of In vitro studies utilizing DATS 
Cancer Type Molecular Targets Mechanism Model Reference 
Prostate 
↑ CyclinB1; ↓ Cdk1; ↑ P-Cdk1; ↓ Cdk1/CyclinB1 kinase 
activity; ↑ CDKN1A (p21Cip1/Wap1); α-tubulin disruption; ↓ 
Cdc25C, ↑ P-Cdc25C; ↑ Cdc25C:14-3-3β; ↑ ROS 
G2/M arrest PC-3, DU145 [87] 
 
↓ ferritin L/H (by proteasomal degradation); ↑ LIP; ↑ ROS; 
↓ P-Cdc25C 
G2/M arrest PC-3, DU145 [88] 
 
↓ APC activity (maintain P-Cdc27/ P-Cdc20); ↓ Chk1; ↑ P-
Histone H3; ↑ P-Securin; ↑ CyclinB1; ↑ H2O2 
G2/M arrest PC-3, DU145 [89] 
 
α-tubulin disruption; ↑ P-Histone H3; ↑ CyclinB1; ↓ Cdk1; 
↑ P-Cdk1; ↓ Cdc25B/C; ↓ APC activity (↑ Cdc27; ↑ P-
Cdc27; ↑ P-Cdh1); ↑ securin; ↑ P-Chk1; ↑ Caspase-3 
activity; ↑ p53; ↑ P-p53 




↓ P-Akt; ↑ P-ERK1/2; ↑ P-p66Shc; ↓ Ferritin H; ↑ LIP; ↑ 
ROS 
G2/M arrest,  
apoptosis 
PC-3 [97, 101] 
 
↓ Bcl-2; ↓ Bcl-XL;↑ Bak; ↓ ΔΨm; ↑ cytosolic Cytochrome 
C; ↑ Caspase-3; ↑ ROS 
Apoptosis LNCaP [112] 
 ↓ Ferritin; ↑ LIP; ↑ ROS; ↑ P-Itch Apoptosis PC-3 [102] 
 
↓ Bcl-2; ↑ P-Bcl-2; ↓ Bax:Bcl-2 heterodimer; ↑ Caspase-
3/9; ↑ P-JNK; ↑ JNK activity; ↑ P-ERK1/2; ↑ ERK1/2 activity 
Apoptosis PC-3, DU145 [119] 
 
↑ DR4/5; ↓ Bcl-2; ↓ Bcl-XL; ↓ Mcl-1; ↑ Bax; ↑ Bak; ↑ Bim; 
↑ NOXA; ↑ PUMA; ↓ XIAP;  ↓ survivin; ↓ cIAP1/2;  ↑ 
Caspase-3/9 activity; ↓ ΔΨm 
Apoptosis PC-3, LNCaP [123] 
 
↓ P-Akt; ↓ Akt activity;↓ P-Bad; ↓ IGF-1R; ↓ P-IGF-1R; ↓ 
PI3-K; ↑ BAD mitochondrial translocation; ↑ Caspase-3; ↑ 
cleaved PARP; ↓ Bad:14-3-3β 
Apoptosis PC-3, DU145 [128] 
 
↓ XIAP (by proteasomal degradation); ↑ cIAP1; ↑ survivin; 
↑ survivin mRNA 
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LNCaP, DU145 [143] 
 
↓ Androgen receptor mRNA; ↓ AR (not by proteasomal 
degradation); ↓ P-AR;  ↓ AR nuclear translocation; ↓ AR 








↑ CyclinB1; ↑ Caspase-3 activity; inhibit spindle formation 






↑ P-Histone H3; ↑ CyclinB1; ↓ Cdk1; ↑ P-Cdk1; ↓ ACP 
activity (↑ P-Cdh1); ↑ securin; ↑ P-Chk1; ↑ Caspase-3 
activity 




↑ ROS; ↓ ΔΨm; ↑ Caspase-3/9 ; ↑ Caspase-3/9 activity; ↑ 












↓ MMP-2/7/9 mRNA; ↓ MMP-2/7/9; ↓ VEGF mRNA; ↓ 
VEGF secretion; ↓ iNOS; ↓ COX II; ↓ uPA; ↓ H/K/N-Ras; ↓ 
RhoA; ↓ FAK; ↓ SoS, ↓ PI3-K; ↓ MKK7; ↓ MEKK3; ↓ 







HT-29, HUVEC [138] 
Breast 
↑ CyclinB1; ↑ CDKN1A (p21Cip1/Waf1); ↑ Bax mRNA; ↑ Bax; ↑ 
p53 mRNA; ↑ p53; ↑ p53 nuclear translocation; ↑ Fas 
mRNA; ↑ Fas; ↓ Bcl-2 mRNA; ↓ Bcl-2; ↓ MDM2; ↓ Akt 
mRNA; ↓ Akt; ↑ CyclinD1 mRNA; ↑ CyclinD1 
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↓ ER-α mRNA; ↓ ER-α; ↓ nuclear ER-α; ↓ ER-α promoter 








↓ ΔΨm; ↑ Caspase-7; ↑ cleaved PARP; ↓ Bcl-2; ↑ P-Bcl-2; 
↓ P-Bad; ↓ ERK1/2 activity; ↓ P-Akt; ↑ P- JNK; ↑ JNK 
activity; ↑ ROS; ↑ AP-1 DNA binding activity (↑ c-Jun; ↑ P-






















↑ ROS; ↑ GRX:TRX oxidation;↑ ASK1 dissociation; ↑ P-JNK; 
↑ P-Bim 
Apoptosis MDA-MB-231 [120] 
 
↓ MMP-2/9 mRNA; ↓ MMP-2/9; ↓ MMP-2/9 activity; ↓ P-









↓ mammosphere formation; ↓ ALDH activity; ↓ 
CD44high/CD24low/ESA+; ↓ Bmi-1 mRNA; ↓ Bmi-1; ↓ uPAR; 
↓ FoxQ1 mRNA; ↓ FoxQ1; ↓ nuclear FoxQ1; ↑ DACH1 







↑ ROS; ↓ ΔΨm; ↑ P-ERK1/2; ↑ P-JNK1/2;  ↑ p53; ↓ Bcl-2; 
↑ survivin 




↓ Bcl-2; ↓ Bcl-XL; ↑ Bax; ↑ Bak; ↑ Bid; ↑ cleaved PARP; ↑ 
CyclinB1; ↓ Cdk1; ↓ P-Cdk1; ↓ Cdc25C 
G2/M arrest,  
apoptosis 




Table 2.1 (Continued) 
 
↓ Bcl-2; ↑ Caspase-3/8/9 mRNA; ↑ Caspase-3/8/9 activity; 
↑ Bax mRNA; ↑ Bax 
Apoptosis A549 [124] 
 ↑ Intracellular Ca2+ Apoptosis A549 [130] 
Skin 
↓ Cdc25C; ↓ Cdk1; ↑ Caspase-3/9; ↑ Caspase-3/9 activity 
↑ ROS; ↑ intracellular Ca2+; ↓ ΔΨm; ↑ P-H2AX; ↑ P-p53; ↑ 
CDKN1A (p21Cip1/Waf1); ↑ Wee1;  ↑ CyclinB1; ↑ cleaved PARP 
G2/M arrest,  
apoptosis 
A375, BCC [96] 
 
↑ ROS; ↑ ɣ-H2AX; ↑ P-p53; ↑ CDKN1A (p21Cip1/Waf1); ↓ 
ΔΨm; ↑ intracellular Ca2+; ↑ GRP78/BiP; ↑ CHOP/GADD153; 
↑ Caspase-3/4/9; ↓ Bcl-2; ↑ P-Bcl-2; ↓ Bcl-XL; ↑ Bax; ↑ 
Cytochrome C release; ↑ Apaf-1; ↑ cleaved PARP; ↑ 
cytosolic HtrA2/OMI; ↑ cytosolic AIF; ↑ nuclear AIF; ↑ 





↓ Bcl-2; ↓ Bcl-XL; ↑ Cytochrome C release; ↑ Caspase-3 
activity; ↑ cleaved PARP 
Apoptosis A375, M14 [127] 
 
Bladder 







↑ Caspase-3/8/9; ↑ Caspase-3/8/9 activity;  ↑ cleaved 
PARP; ↑ DR4/5; ↑ Fas; ↑ FasL; ↑ TRAIL; ↑ Bax; ↓ Bcl-2; ↓ 






↓ MMP-2/9 mRNA; ↓ MMP-2/9; ↓ MMP-2/9 activity; ↑ 










↑ Chk1 activity; ↑ CyclinB1; ↑ P-securin; ↑ P-histone H3; ↓ 
APC activity (↑ P-Cdc20, ↑ P-Cdh1); ↑ ATR activity 
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↓ VEGF mRNA; ↓ VEGF secretion; ↓ Notch-1 mRNA; ↓ 
Notch-1; ↓ Hes-1 mRNA; ↓ Hes-1; ↓ Hey-1/2 mRNA; ↓ 
CyclinD1,; ↓ MMP-2/9 mRNA; ↓ MMP-2/9; ↓ MMP-2/9 









Glioblastoma ↑ ROS; ↓ ΔΨm; ↑ Caspase-9 activity Apoptosis T98G, U87MG [111] 
     
Liver ↑ CyclinB1; ↓ Cdk1 G2/M arrest J5 [85] 
 
↑ NQO1 mRNA; ↑ HO-1 mRNA;↑ ARE promoter activity; ↑ 









↑ Bax mRNA; ↑ Bax; ↓ Bcl-2 mRNA; ↓ Bcl-2; ↑ p53 mRNA; 
↑ p53; ↑ p53 nuclear translocation;  ↓ MDM2; ↓ Akt; ↑ 






Gastric ↓ Bcl-2; ↓ Caspase-3; ↓ Caspase-3 activity Apoptosis BGC823 [126] 







↑ CyclinB1; ↑ caspase-3; ↑ IκB-α; ↓ p- IκB-α; ↓ CyclinD1 
mRNA; ↓ CyclinD1; ↑ Bax; ↓ XIAP; ↓ p-p65; ↑ cytoplasmic 
p65; ↓ nuclear p65; ↑ MT2A mRNA; ↑ MT2A; ↑ H3K9ac; ↑ 
H4K5ac; ↓ HDAC1/2; ↑ IκB-α promoter activity 









↑ Caspase-3 activity 
 







↑ PUMA mRNA; ↑ PUMA; ↑ Bax mRNA; ↑ Bax; ↓ Bcl-2 
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Table 2.2: Summary of In vivo studies utilizing DATS 
Cancer Type Effects Mechanism Dose Model Reference 
Prostate 
↓ tumor growth; ↑ DR4/5; ↓ Bcl-2; ↓ 
Bcl-2; ↓ Bcl-XL; ↑ Bax; ↑ Bak; ↓ 
microvessel density; ↓ VEGF; ↓ IL-6; ↓ 














 ↓ XIAP; ↑ survivin 
Inhibited cancer 
progression, apoptosis 




  ↓ STAT-3; ↓ P-STAT3 
Inhibited migration and 
invasion 




  ↓ androgen receptor 
Altered hormone 
signaling 





↓ poorly differentiated carcinoma; ↑ 
well differentiated carcinoma and 
prostatic intraepithelial neoplasm; ↓ 
pulmonary and pelvic lymph node 
metastases; ↓ proliferation; ↓ 
neuroendocrine differentiation; ↑ 


































Table 2.2 (Continued) 
Breast 
 














↓ metastatic foci; ↓ maximal 
metastatic distance 



























↓ COX-2; ↓ AP-1 DNA binding (↓ c-Jun; 
↓ c-Fos);↓ P-JNK; ↓ JNK activity; ↓ P-
Akt; ↓ Akt activity; ↓ tumor incidence 




5 and 25μM 
topically 




↓ tumor growth; ↓ HDAC activity; ↑ 
histone H3/4 acetylation; ↓ Cdk1; ↓ 
Cdc25C; ↑ CDKN1A (p21Cip1/Wap1); ↑ 
p53; ↓ MDM-2; ↓ survivin; ↑ mcalpin; 
↓ P-Akt; ↓ c-Myc; ↓ mTOR; ↓ VEGF; 
↑ calpain; ↑ Bax; ↓ Bcl-2; ↑ caspase-3; 
↑ ICAD degradation 
Inhibited cancer 
progression, G2/M 
arrest, apoptosis  
10ug/kg – 
10mg/kg; 


















Table 2.2 (Continued) 
 
↓ tumor size; ↓ tumor weight; ↑ 
MT2A; ↑ IκB-α; ↑ CyclinB1; ↓ 





every 4 days; 







↑ cell surface markers (CD11b, Mac-3); 
↑ macrophage activity; ↑ NK cell 















CHAPTER 3. EFFECT OF DIALLYL TRISULFIDE ON HEDGEHOG SIGNALING IN 
PANCREATIC CANCER CELLS 
3.1 Introduction 
Pancreatic Cancer (PC) is among the deadliest cancer types with an overall 5-year 
survival rate of only 8% [1]. A large contributor to PC mortality stems from the fact that 
over half of cases are diagnosed after distant metastasis has occurred [1]. In the case of 
late diagnoses, adjuvant treatment strategies of chemo- and/or radiation therapy have 
not proven successful over the past 40 years. Even in the case of curative resection, 80-
85% of patients experience metastasis and local relapse [9]. Current research in the area 
of chemoprevention aims to increase survival at all stages of PC by reducing disease 
progression. 
Bioactive compounds found in fruits and vegetables are an attractive source of 
putative chemopreventive agents due to their wide applicability and association with 
low toxicity. Evidence showing an inverse correlation between cancer risk and fruit and 
vegetable intake provided the first evidence that consumption of these foods may have 
chemoprotective effects. Further characterization of specific components from fruits 
and vegetables and their application in cell based and preclinical cancer models suggests 
certain bioactive compounds in whole foods have anti-cancer capabilities. Diallyl 
trisulfide (DATS), a compound derived from Allium vegetables such as garlic and onions, 
has been shown to regulate multiple cancer hallmark pathways including apoptosis, 
evasion of cell cycle arrest, angiogenesis, and invasion and metastasis [29, 30]. Previous 
work has shown accumulation of PC cells in G2/M phase, increased expression of 
phosphorylated Histone H3 (p-H3), enhanced expression of p21, and phosphorylated 
CyclinB1 [109]. These results indicate maximum cell cycle arrest following 16 hours of 
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DATS treatment which has been shown to cause apoptosis [109, 164]. Previous studies 
have also shown reduced survival as well as increased cytoplasmic histone associated 
DNA fragmentation in PC cells following DATS treatment [165]. Induction of the 
apoptosis inducing proteins Bim and cleaved caspase-3, enhanced protein expression of 
inactive apoptosis inhibitor Bcl-2, as well as increased levels of apoptosis marker cleaved 
PARP have also been observed [109, 165]. 
Another pathway, the Hedgehog (Hh) pathway, is of great interest for PC 
prevention in light of its role in pancreatic carcinogenesis [32]. Hh signaling is activated 
when a Hh ligand such as Sonic Hedgheog (Shh) binds to the Patched (Ptch) receptor. 
This relieves inhibition of Smoothened (Smo) leading to its shuttling to the primary cilia. 
Smo present in cilia induces release of the Gli1 transcription factor from its repressor 
Suppressor of Fused Homolog (SuFu) leading to Gli1 nuclear translocation. There, it 
enhances transcription of target genes with known roles in enhancing cancer hallmark 
pathways. Hh signaling is tremendously important during normal embryonic 
development but has been shown to be aberrantly activated in many cancer types. 
Furthermore, aberrant activation of this pathway is associated with reduced survival of 
PC patients. If a compound is able to inhibit the Hh pathway, it may prove invaluable for 
reducing PC progression and improving survival.  
Multiple PC cell lines representing a spectrum of mutations and characteristics 
were used in this study. All cell lines are poorly differentiated but were derived from 
different locations [166]. AsPC-1 cells were derived from the ascites while BxPC-3, MIA 
PaCa-2, and PANC-1 cells lines were derived from the primary pancreatic tumor [166]. 
These cell lines differ in the status of Kras as well as p16, two genes estimated to be 
mutated in 95% of PDAC tumors [5, 167]. BxPC-3 possesses wild type Kras while the 
other cell lines are mutated at amino acid 12 [166]. MIAPaCa-2 and PANC-1 PC cells 
possess a homozygous deletion in p16 while conflicting evidence exists regarding the 
status of p16 in AsPC-1 and BxPC-3 [166]. These cell lines also exhibit varying degrees of 
Hh pathway component expression. AsPC-1 and PANC-1 PC cells display the highest 
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levels of Gli1 mRNA expression so they were chosen for investigation of the Hh pathway 
[168]. 
The Hh pathway is a desirable target in PC prevention because of its regulatory 
overlap with multiple cancer hallmark pathways, high degree of mutation in PC, and 
additional involvement with cancer stem cell characteristics. This study was undertaken 
to investigate Hh regulation by DATS as well as to elucidate the role of Hh pathway 
signaling in PC cells. The first goal of this work was to characterize the effect of DATS on 
Hh pathway components. We hypothesized that DATS treatment of PC cells would result 
in downregulation of the Hh pathway. Another goal of this study was to elucidate the 
mechanistic significance of Gli1 as it relates to cancer hallmark pathways. To this end, 
we chose to overexpress Gli1 and observe the downstream consequences in the cell 
cycle and apoptosis. Specifically, protein expression of mitotic cell marker p-H3 and 
apoptosis indicator cleaved PARP were examined with and without DATS treatment. 
In the present study, we observed reduced colony formation of two PC cell lines 
following DATS treatment. We provide the first evidence that DATS regulates the Hh 
pathway constituent Gli1 by inhibiting mRNA and protein expression in AsPC-1 cells. 
DATS is also shown to enhance protein expression of Hh pathway components Shh and 
Ptch. 
 
3.2 Materials and Methods 
Chemicals And Reagents 
Diallyl trisulfide was purchased from LKT Laboratories (St. Paul, MN). DMSO was 
obtained from Fisher Scientific (Pittsburg, PA). Gli1 (cs2534s), p-H3 (cs3377s), and PARP 
(9548s) antibodies were purchased from Cell Signaling (Danvers, MA). Mouse β-actin 
(A5441) antibody was purchased from Sigma-Aldrich (St. Louis, MO). Shh (sc1194), 
Patched (sc9016) and anti-goat (sc2020) antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti-mouse (95017-336) and anti-rabbit (95017-556) 
secondary antibodies were purchased from GE Healthcare (Radnor, PA). Goat anti-rabbit 




MIAPaCa-2, BxPC-3, AsPC-1, and PANC-1 cell lines were purchased from 
American Type Culture Collection (Manassas, VA). MiaPaCa-2 were cells were grown in 
DMEM (Corning Inc., Corning, NY) supplemented with 10% fetal bovine serum (FBS) and 
2.5% donor horse serum. BxPC-3 cells were grown in RPMI-1640 (Corning) with final 
concentration of 4.5 g/L glucose (Corning), 10mM HEPES (Corning), and 1mM sodium 
pyruvate (Corning) in addition to 10% FBS. AsPC-1 cells were grown in RPMI-1640 
supplemented with 10% FBS. PANC-1 cells were grown in DMEM supplemented with 10% 
FBS. All media were additionally supplemented with 1% penicillin/streptomycin (10,000 
U/ml penicillin, 10 mg/ml streptomycin). Cells were maintained at 37°C with 95% air and 
5% CO2. 
 
Clonogenic Survival Assay 
Clonogenic assay was completed as described previously [169]. To summarize, 
cells were plated in 100-mm plates and allowed to attach overnight. Cells were treated 
with either DMSO (vehicle) or DATS (20, 40, 60 μmol/L) for 24 hours. Cells were 
trypsinized and re-seeded in 6-well plates at 300 cells/well in normal growth media 
lacking DATS. Medium was replaced every 3 days for 10 (MIAPaCa-2) or 14 (BxPC-3) 
days. Colonies were fixed with methanol and stained with 0.5% (w/v) crystal violet 
(Amresco, Bridgeport, NJ) in 20% methanol. Only colonies larger than 50 densely 
populated cells were counted. 
 
Western Blot Analysis 
Western blotting procedure was completed as described elsewhere [169]. In 
short, cells were plated in 100-mm plates and allowed to attach overnight. Cells were 
treated with either DMSO (vehicle) or DATS (20, 40, 60 μmol/L) for 16 or 24 hours. Cells 
were collected by cell scraping and pellets were frozen at -80°C. Cell pellets were then 
lysed with buffer containing final concentrations of 1% Triton X-100, 0.1% SDS, 50mM 
Tris, and 150mM NaCl with added 1x protease and phosphatase inhibitor cocktails 
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(Sigma-Aldrich, St. Louis, MO). Protein concentration was determined by Bradford assay 
(Bio-Rad, Philadelphia, PA). Protein samples were loaded and separated by SDS-PAGE 
according to expected protein weight. Proteins were transferred to PVDF membranes 
(Perkin Elmer, Waltham, WA) by wet electrotransfer. Following blocking for 2 hours at 
room temperature, membranes were incubated in primary antibody overnight at 4°C. 
Membranes were washed 3 times in Tris-buffered saline with Tween-20 and incubated 
in secondary antibody at room temperature for 1 hour. The membranes were then 
washed 3 times for 15 minutes each. Proteins were visualized on X-ray film using the 
enhanced chemiluminescence detection system (GE Healthcare, Pittsburgh, PA). 
 
Real Time Quantitative Reverse-Transcription Polymerase Chain Reaction 
Total RNA was isolated and purified from frozen cell pellets following 
manufacturer’s protocol using the PureLink RNA Mini Kit (Life Technologies, Carlsbad, 
CA) and PureLink DNase Kit (Invitrogen, Carlsbad, CA). cDNA was synthesized using the 
BioRad iScript cDNA Synthesis Kit (Hercules, CA). Primers for Gli1 (Forward: 5’-CAT CAG 
GGA GGA AAG CAG AC-3’, Reverse: 5’-CAT TGC CAG TCA TTT CCA CAC-3’), Shh (Forward: 
5’- CTC GTA GTG CAG AGA CTC CT-3’, Reverse: 5’- GAG CGG ACA GGC TGA TG-3’), Smo 
(Forward: 5’-GAA GAT CAA CCT GTT TGC CAT G-3’, Reverse: 5’-TTT GGC TCA TCG TCA 
CTC TG-3’) and GAPDH (Forward: 5’-GGA GCG AGA TCC CTC CAA AAT-3’, Reverse: 5’-
GGC TGT TGT CAT ACT TCT CAT GG-3’) were purchased from Integrated DNA 
Technologies (Coralville, IA). Quantitative real-time PCR was performed using a 
LightCycler 96 system (Roche, Basel, Switzerland). Target sequences were amplified at 
95°C for 10 minutes, followed by 45 cycles of a 3-step amplification consisting of 95°C 
incubation for 15 seconds, 60°C for 10 seconds, and 72°C for 30 seconds. Fold change 
was calculated relative to GAPDH control using the 2-ΔΔCt method. 
 
Immunofluorescence 
Immunofluorescence was carried out as described previously [170]. Briefly, cells 
were plated on coverslips and allowed to attach overnight at 37°C (5% CO2). Cells were 
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then incubated with DMSO (vehicle) or DATS (40 and 60 μmol/L) for 16 hours. Following 
media removal, cells were washed with PBS and fixed with 2% paraformaldehyde 
overnight at 4°C. Cell membranes were permeabilized with 0.5% Triton X-100 in PBS for 
15 minutes at room temperature and blocked for 1 hour with buffer containing final 
concentrations of 0.5% BSA and 0.15% glycine. Coverslips were incubated in primary 
antibody diluted in blocking buffer for 2 hours at room temperature followed by 3 
washes with blocking buffer. Anti-rabbit AlexaFluor 568 secondary antibody was diluted 
in blocking buffer and incubated on coverslips for 1 hour. Cells were counterstained 
with 500 ng/mL DAPI (Invitrogen, Carlsbad, CA) and visualized on a Nikon Eclipse TE300 
microscope using SPOT Advanced software. 
 
Transient Transfection and Gli1 Overexpression 
AsPC-1 cells were plated in 6 well plates at 100,000 cells per well 24 hours prior 
to transfection with 1 μg plasmid DNA. A 1:3 plasmid:FuGene6 transfection reagent 
ratio was used (Qiagen, Valencia, CA). pCMV6-Gli1 (RC201110) and pCMV6-Entry 
(PS100001) plasmids were purchased from Origene (Rockville, MD). Following 24 hours 
of transfection, cells were treated with DMSO (vehicle) or DATS (60 μmol/L) for 16 hours. 
Cells were collected, lysed, and analyzed by Western Blot as described. 
 
Statistical Analysis 
Protein band quantification utilized UN-SCAN-IT software (Silk Scientific, Orem, 
UT). Statistical analysis was done using Graph Pad Prism 9.1 (La Jolla, CA). One-way 
ANOVA followed by Dunnett’s multiple comparisons test was used to calculate 
significant differences for all experiments except transfections. For transfection 
experiments, unpaired Student’s t-test was performed to determine significant 
differences between groups. Values are presented as mean ± SEM. A P-value of less 





DATS reduced colony formation of pancreatic cancer cells 
To determine the effect of DATS on PC cell colony formation, we performed a 
clonogenic assay. Treatment of MIAPaCa-2 and BxPC-3 cells with DATS for 24 hours 
caused a dose dependent decrease in clonogenic survival after 10-14 days of colony 
growth (Figure 3.1). Treatment with 20, 40, and 60 μmol/L DATS reduced colony 
formation of MIAPaCa-2 cells by 15, 27, and 42% respectively (Figure 3.1 A). BxPC-3 
colony formation decreased by 19, 39, and 50% with similar DATS treatments (Figure 3.1 
B). Additionally, smaller average colony were observed size with increasing DATS 
concentration in both cell lines (Figure 3.1 A and B). 
 
Figure 3.1 DATS inhibits colony formation of pancreatic cancer cells 
Clonogenic survival of (A) MIAPaCa-2 and (B) BxPC-3 pancreatic cancer cells. Column 
represents mean (n=2); bar represents SEM. *,  significantly different from vehicle 





DATS decreased the protein and mRNA expression of Gli1 in AsPC-1 pancreatic cancer 
cells 
We analyzed the effect of DATS on Gli1 expression in AsPC-1 and PANC-1 PC cells 
lines. In AsPC-1 cells, we observed reduced Gli1 protein expression by Western blot 
following DATS treatment for 16 and 24 hours (Figure 3.2 A). All protein expression  
 
Figure 3.2 DATS treatment reduces levels of Gli1 protein and mRNA in AsPC-1 pancreatic 
cancer cells 
(A) Western blot of Gli1 in AsPC-1 cells following 16 and 24 hours of DATS treatment. 
Data of representative experiment are shown. (B) Densitometry analysis of Western 
blots. Column represents mean (n=2); bar represents SEM. *,  significantly different 
from vehicle treated of specified time point, P<0.05, by one way ANOVA followed by 
Dunnett’s multiple comparisons test. (C) qPCR analysis of Gli1 in AsPC-1 cells following 
16 and 24 hours of DATS treatment. Column represents mean (n=2); bar represents SEM. 
*,  significantly different from vehicle treated of specified time point, P<0.05, by one 
way ANOVA followed by Dunnett’s multiple comparisons test. 
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levels in 16 hour treated AsPC-1 cells were significantly different compared to vehicle 
treatment following densitometry analysis. Gli1 protein expression was reduced up to 
85 and 69% compared to control after 16 and 24 hours of 60 μmol/L DATS treatment 
respectively in AsPC-1 cells (Figure 3.2 B). These results were supported by a reduction 
in Gli1 protein fluorescence observed comparing vehicle and 40 μmol/L DATS treated 
AsPC-1 cells (Figure 3.3). Gli1 mRNA displayed a 55 and 58% reduction in Gli1 mRNA 
expression following 60 μmol/L DATS treatment for 16 and 24 hours respectively (Figure 
3.2 B). Treatment of PANC-1 cells with DATS for 16 and 24 hours caused no significant 
change in Gli1 protein or mRNA expression level compared to vehicle treated cells. 
(Figure 3.4 A – C). 
 
 
Figure 3.3 DATS treatment reduces Gli1 immunofluorescence in AsPC-1 pancreatic 
cancer cells 
Images showing fluorescence of nuclear DNA (blue) and Gli1 (red) in AsPC-1 cells 
following treatment with vehicle and 40 µmol/L DATS for 16 hours. Representative 




Figure 3.4 Gli1 protein expression is minimally affected in PANC-1 cells 
(A) Western blot of Gli1 in PANC-1 cells following 16 and 24 hours of DATS treatment. 
Data of representative experiment are shown. (B) Densitometry analysis of Western 
blots. Column represents mean (n=2); bar represents SEM. Statistics analyzed by one 
way ANOVA followed by Dunnett’s multiple comparisons test. (C) qPCR analysis of Gli1 
in PANC-1 cells following 16 hours of DATS treatment. Column represents mean (n=2); 
bar represents SEM. Statistics analyzed by one way ANOVA followed by Dunnett’s 
multiple comparisons test. 
 
DATS modulated protein expression of other Hh pathway constituents 
Analysis of Shh, Ptch, and Smo protein level in response to DATS treatment was 
done by Western blot. In AsPC-1 cells, full length Shh protein increased greater than 3-
fold with 60 μmol/L DATS treatment at both 16 and 24 hour time points compared with 
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untreated cells (Figure 3.5 A). Levels of the N-terminal, physiologically active peptide 
were also increased following DATS treatment by 2.8 (±1.4) and 1.9-fold (±0.45) 
following 60 μmol/L treatment for 16 and 24 hours respectively when compared with 
vehicle treated cells (Figure 3.5 A). DATS treatment increased Ptch protein expression in 
AsPC-1 cells by up to 2.1-fold (±0.66) following 16 hour treatment and 3.5-fold (±1.9) 
following 24 hour treatment relative to control (Figure 3.5 B). Expression of Smo was 
largely unaffected in all treatments at both 16 and 24 hour time points (Figure 3.5 C) 
 
Figure 3.5 Treatment with DATS modulates expression of other Hedgehog pathway 
components in AsPC-1 cells 
Western blot s of (A) Shh, (B) Ptch, and (C) Smo in AsPC-1 cells following 16 and 24 hours 
of DATS treatment. Data of representative experiment are shown. Relative expression 




Effect of Gli1 overexpression on mitotic cell marker p-H3 and apoptosis marker cleaved 
PARP 
 To investigate the mechanistic role of Gli1 in PC cells, AsPC-1 cells were 
transiently transfected with Gli1 using the pCMV6-Gli1 plasmid. An average 4.4-fold 
(±0.50) increase in the 160kD isoform of Gli1 was achieved. Following 60 μmol/L DATS 
treatment for 16 hours, Gli1 protein expression was reduced to 27% of untreated levels 
in empty vector transfected cells (P = 0.007). In Gli1 transfected cells, DATS treatment  
 
Figure 3.6 Gli1 overexpression shows a trend toward decreased p-H3 and cleaved PARP 
expression following DATS treatment 
(A) Western blot of Gli1 in AsPC-1 cells following transfection with pCMV6-Entry (Empty 
Vector) or pCMV6-Gli1 (Gli1 Plasmid) and treatment with 60 µmol/L DATS for 16 hours. 
(B) Densitometry analysis of Western blots. Column represents mean (n=2); bar 
represents SEM. Different letters signify significant differences from Empty Vector, 
vehicle treatment, P<0.05, by unpaired, two-tailed Student’s t-test. Western blots of (C) 
p-H3 and (D) PARP from Gli1 overexpression experiments. Data of representative 




resulted in a 58% reduction of Gli1 protein (P = 0.039) (Figure 3.6 A and B). Protein levels 
of mitotic cell marker p-H3 were significantly increased in empty vector and Gli1 
transfected cells after 16 hours of 60 μmol/L DATS treatment (Figure 3.6 C). Protein 
expression of apoptosis marker cleaved PARP was also determined by Western blot. 
DATS treatment increased cleaved PARP expression in empty vector and Gli1 plasmid 
transfected cells (Figure 3.6 D). 
 
Figure 3.7 Summary of the effects of DATS on Hh signaling in pancreatic cancer cells 
 
3.4 Discussion 
In this study, PC cells displayed reduced clonogenic survival following DATS 
treatment. Here we also provide the first evidence of regulation of the Hh pathway in PC 
cells following DATS treatment. Expression of the transcription factor Gli1 was inhibited 
following DATS incubation of AsPC-1 cells although PANC-1 cells were less effected. Shh 
and Ptch protein expression were increased upon DATS treatment of AsPC-1 cells while 
protein levels of pathway mediator Smo were largely unaffected. A summary of these 
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effects is shown in Figure 3.7. Following Gli1 overexpression, DATS was shown to target 
exogenous Gli1 protein. Additionally, G2/M marker p-H3 was as well as apoptosis 
marker cleaved PARP were induced upon DATS treatment. Gli1 overexpressing cells 
exhibited a trend toward reduced p-H3 as well as cleaved PARP expression suggesting 
Gli1 may have mechanistic involvement with cell cycle and apoptosis mechanisms 
though these results are overall inconclusive. 
The PC cell lines used in these experiments represent a variety of key mutations, 
invasive capabilities, migration capacities, and tumorigenic potential. Many sources of 
cancer tumor heterogeneity exist including between patients, between metastases, and 
within primary as well as metastatic tumors [171]. Multiple PC cell lines were used in 
this study to better understand how DATS affects cells representing a spectrum of 
origins, mutations, and characteristics – a vital aspect of determining the potential of 
DATS as a chemopreventive agent. 
MIAPaCa-2 cells have been characterized as having high colony formation ability, 
which is consistent with our findings in the clonogenic survival assay [172]. BxPC-3 has 
been characterized as having no colony formation ability [173] which is in opposition to 
our observations. Differences in clonogenic survival assay procedure including growing 
conditions and allotted growth time may account for this discrepancy. Reductions in 
both colony size and number with increasing DATS treatment suggest DATS inhibits 
growth and survival of MIAPaCa-2 and BxPC-3 PC cells. Because cells were grown in 
media lacking DATS for 10-14 days following a 24 hour DATS incubation, the fact that 
colonies from treated cells were smaller and less numerous suggests DATS permanently 
or semi-permanently alters programs in PC cells to favor reduced clonogenic survival. 
Inhibition of cell cycle progression as well as induction of apoptosis by DATS are possible 
explanations for these results. Previous data from our lab have shown DATS-induced 
G2/M arrest as well as increased p-H3 expression in MIAPaCa-2 and PL45 PC cells [109]. 
Additionally, it has been shown that DATS reduced viability and induced apoptosis in PC 
cell lines Capan-2 and H6C7 [106]. Previous data indicated MIAPaCa-2 cells exhibit 
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reduced survival following DATS treatment as well as modulation of Bim and 
phosphorylated Bcl-2 protein expression [109, 165].  
 Inhibition of the Hh pathway is a desirable goal because of its involvement in 
carcinogenesis including propagation of cancer hallmark pathways as well as cancer 
stem cell characteristics [32]. Others have shown bioactive agents including 
sulforaphane, curcumin, and genistein to regulate the Hh pathway in various cancer cell 
types [37], but the effect of DATS on Hh signaling in PC cells has never been investigated. 
In general, results regarding Hh pathway modulation by dietary agents in cancer cells 
have shown reduced mRNA and protein expression of Hh pathway constituents Shh, 
Ptch, Smo, and Gli1 [37]. Observed reductions in Gli1 nuclear translocation, reporter 
activity, and downstream target expression including CyclinD1 and Bcl-2 show that these 
agents not only inhibit Hh pathway constituent expression, but overall pathway activity 
[37]. Additionally, induction of downstream effects such as increased cell cycle inhibition 
and apoptosis markers indicate that dietary agents such as curcumin, resveratrol, and 
epigallocatechin 3-gallate have potential as chemopreventive Hh inhibitors [37]. 
Mechanistic understanding of how bioactive compounds specifically inhibit the Hh 
pathway is largely lacking. In this study, we aimed to understand how DATS regulates 
multiple Hh pathway constituents on the mRNA and/or protein level as well as elucidate 
the mechanistic significance of Gli1 in PC cells. 
 In the present study, DATS was shown to inhibit mRNA and protein expression of 
the Hh pathway transcription factor Gli1 at 16 and 24 hour time points in AsPC-1 PC cells. 
Because Gli1 is the downstream effector of the pathway, these findings suggest DATS 
may ultimately cause Hh pathway inhibition. These results are noteworthy when 
considering the chemopreventive applicability of DATS as recent clinical trials of Smo 
inhibitor IPI-926 plus gemcitabine significantly reduced median survival in metastatic PC 
patients when compared with gemcitabine treatment alone [174]. It is not mentioned in 
the study whether tumors were able to evade Smo inhibition or if the drug combination 
induced disease progression. Because DATS targets the downstream effector Gli1, the 
likelihood that a tumor may circumvent its effect or that DATS would contribute to 
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disease advancement is low. PANC-1 PC cells exhibited more resistance to DATS 
treatment supporting the need for continued research regarding a variety of cell types. 
It is possible, though, that enhanced drug efflux capacity is responsible for this effect. 
While the DATS concentrations used in this study ranged from 20 – 60 μmol/L, other 
studies utilizing upwards of 100 μmol/L DATS have been carried out [106, 134]. The 
applicability of such a concentration is yet to be tested in vivo, but it is possible that 
PANC-1 cells would exhibit a response on the Gli1 mRNA and protein level under such 
conditions.  
 The presented data are particularly striking in light of the observed increases in 
Shh and Ptch protein expression as well as relatively unchanged Smo expression. To 
date, very few studies have reported increased or unchanged Hh pathway constituent 
expression following treatment with a chemopreventive dietary agent. One study 
suggested that Med283 medulloblastoma cells and HSR-GBM1 neurosphere cells were 
largely resistant to curcumin treatment as an explanation for the minimal change in Ptch 
and Gli1 mRNA expression that showed a mild tendency towards increased expression 
in some treatments [175]. Because a reduction in Gli1 mRNA and protein were observed 
in AsPC-1 cells, overall cell line resistance is unlikely. Another study of medulloblastoma 
cells reported reduced Shh protein expression following 8 hours of curcumin treatment 
that increased greater than 5-fold by the 24 hour time point [38]. This could presumably 
be a result of stem cell enrichment as observed in another study of PC cells treated with 
gemcitabine [172]. Again, because DATS targets the eventual effector of a stem cell 
related pathway, this likely does not explain the present results. Expression of Shh is 
driven by multiple transcription factors including p63, NF-κB, TAp73β, and ERα [32]. 
Because little is known about regulation of p53 family members TAp73β and p63 in PC 
cells, induction of Shh via these pathways following DATS treatment cannot be ruled out. 
In one study, treatment of ovarian cancer cells with the chemotherapeutic drug 
paclitaxel induced expression of TAp73β [176]. If this effect was observed in PC cells, it is 
plausible that Shh expression would be increased as observed in this study. DATS has 
been shown to reduce expression of ERα and NF-κB in multiple cancer cell types making 
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the action of these pathways an unlikely explanation for the observed increased Shh 
protein expression [100, 110]. Outside of being a product of Gli1 activation, few studies 
have examined regulation of Ptch expression. Some have declared Ptch to be a tumor 
suppressor because of its constitutive inhibition of Smo. Interestingly, though, reduced 
Gli1 expression did not lead to reduced Ptch presence in this study. Elucidation of the 
mechanism by which Ptch protein expression increases is required to more fully 
understand Hh pathway regulation. 
 Another goal of this study was to characterize the mechanistic significance of 
Gli1 downregulation in PC cells. To this end, AsPC-1 PC cells were transiently transfected 
with a pCMV6-Gli1 plasmid. Our data show that DATS targets exogenous Gli1 further 
supporting its role as a Gli1 inhibitor. Because Hh regulates multiple cancer hallmark 
pathways, we sought to gain insight into its role in cell cycle progression. During mitosis, 
DNA is condensed by wrapping around histone proteins. One protein, Histone H3, exists 
in the phosphorylated form beginning during chromosome condensation through 
metaphase and is rapidly dephosphorylated beginning in anaphase. Therefore, 
increased p-H3 is a quality marker for cells in G2/M transition. Following DATS 
treatment of vector and Gli1 transfected AsPC-1 cells, we observed significant increases 
in p-H3 protein suggesting cells were arrested in G2/M phase. These results support 
previous findings from our lab that DATS significantly induced G2/M arrest and induced 
p-H3 expression in MIAPaCa-2 cells following 8 and 16 hours of DATS treatment [109]. 
We observed that Gli1 overexpressing cells treated with DATS exhibited reduced p-H3 
expression compared to vehicle treated, mock transfected cells although this difference 
did not reach statistical significance. Examining protein expression of cleaved PARP is a 
quality marker for apoptosis because PARP is a substrate for executioner caspases thus 
indicating the degree of apoptosis pathway induction. In this study, we observed an 
increase in PARP expression following DATS treatment in both empty vector and Gli1 
plasmid transfected cells. As others have reported, this indicates DATS is a potent 
inductor of apoptosis [99, 114, 121]. Investigation of the mechanistic significance of Gli1 
downregulation on PARP expression yielded no significant effect and requires further 
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investigation to more precisely elucidate the mechanism by which Gli1 interacts with 
these and other cancer hallmark pathways. 
The hypothesis that DATS down regulates the Hh pathway is supported by the 
finding that Gli1 expression is inhibited in AsPC-1 cells. Observed increased expression 
of Shh and Ptch protein levels necessitate further research in this area to determine the 
mechanism by which DATS exerts its effects in PC cells. Further investigation into the 
mechanistic significance of Gli1 down regulation in PC cells is also required.
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CHAPTER 4. CONCLUSION 
In this study, we tested the hypothesis that DATS down regulates the Hh pathway in 
PC cells. This would provide the first evidence as to the modulation of the Hh pathway in 
cancer cells using DATS, a bioactive compound derived from Allium vegetables with 
known anti-cancer capabilities. We chose to target the Hh pathway in PC cells because 
of its significance in PC etiology as a known regulator of important pathway in both 
transit amplifying cells as well as cancer stem cells. The results of a clonogenic survival 
assay suggest DATS has a lasting effect on cell growth in MIAPaCa-2 and BxPC-3 PC cells. 
While growth and survival are endpoints for many upstream signals, it is possible that 
Hh inhibition by DATS is partially responsible for these effects. We chose to focus on 
AsPC-1 and PANC-1 PC cells for determination of the effect of DATS on Hh pathway 
constituents because they exhibit high expression of various pathway components [168]. 
In this study, we observed markedly reduced mRNA and protein expression of the Hh 
pathway component Gli1 in AsPC-1 cells while the effect of DATS on overall Hh pathway 
activity requires further investigation. This effect was not observed in PANC-1 cells 
suggesting they may be more resistant to DATS. Interestingly, we observed increased 
protein expression of two proteins upstream in the Hh pathway, Shh and Ptch along 
with very little change in Smo expression. These findings necessitate more research as 
they may display a novel mechanism by which DATS may prevent the advance of cancer. 
 Because little is known regarding the mechanism of Hh regulation in PC cells, 
Gli1 was overexpressed in AsPC-1 cells and its effect on p-H3 and cleaved PARP protein 
expression was examined. No significant effect of Gli1 overexpression on p-H3 or PARP 
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protein levels were observed although this study requires further investigation. This 
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